KMDS
E-submission
Search
- Page Path
- HOME > Search
Review Article
- Environmental Risk Factors for Progressive Supranuclear Palsy
- Hee Kyung Park, Sindana D. Ilango, Irene Litvan
- J Mov Disord. 2021;14(2):103-113. Published online May 26, 2021
- DOI: https://doi.org/10.14802/jmd.20173
- 10,154 View
- 277 Download
- 5 Web of Science
- 7 Crossref
-
Abstract
PDF - Typically, progressive supranuclear palsy (PSP) is clinically characterized by slow vertical saccades or supranuclear gaze palsy, levodopa-resistant parkinsonism with predominant axial symptoms, and cognitive executive impairment. Over the past decades, various PSP phenotypes, including PSP with predominant parkinsonism, PSP with corticobasal syndrome, PSP with progressive gait freezing, and PSP with predominant frontal dysfunction, have been identified from pathologically confirmed cases. Expanding knowledge led to new diagnostic criteria for PSP that with increased disease awareness led to increased PSP prevalence estimates. The identification of environmental and modifiable risk factors creates an opportunity to intervene and delay the onset of PSP or slow disease progression. To date, despite the increasing number of publications assessing risk factors for PSP, few articles have focused on environmental and lifestyle risk factors for this disorder. In this article, we reviewed the literature investigating the relationship between PSP and several environmental and other modifiable lifestyle risk factors. In our review, we found that exposures to toxins related to diet, metals, well water, and hypertension were associated with increased PSP risk. In contrast, higher education and statins may be protective. Further case-control studies are encouraged to determine the exact role of these factors in the etiopathogenesis of PSP, which in turn would inform strategies to prevent and reduce the burden of PSP.
-
Citations
Citations to this article as recorded by
- Parkinson’s Disease is Predominantly a Genetic Disease
Shen-Yang Lim, Christine Klein
Journal of Parkinson's Disease.2024; 14(3): 467. CrossRef - Progressive supranuclear palsy’s economical burden: the use and costs of healthcare resources in a large health provider in Israel
Yael Barer, Raanan Cohen, Meital Grabarnik-John, Xiaolan Ye, Jorge Zamudio, Tanya Gurevich, Gabriel Chodick
Journal of Neurology.2023; 270(8): 3770. CrossRef - The Pesticide Chlordecone Promotes Parkinsonism-like Neurodegeneration with Tau Lesions in Midbrain Cultures and C. elegans Worms
Valeria Parrales-Macias, Patrick P. Michel, Aurore Tourville, Rita Raisman-Vozari, Stéphane Haïk, Stéphane Hunot, Nicolas Bizat, Annie Lannuzel
Cells.2023; 12(9): 1336. CrossRef - The prevalence and incidence of progressive supranuclear palsy and corticobasal syndrome: a systematic review and meta-analysis
Shane Lyons, Dominic Trépel, Tim Lynch, Richard Walsh, Sean O’Dowd
Journal of Neurology.2023; 270(9): 4451. CrossRef - Analysis of Genetic and MRI Changes, Blood Markers, and Risk Factors in a Twin Pair Discordant of Progressive Supranuclear Palsy
Aliz Persely, Beatrix Beszedics, Krisztina Paloczi, Marton Piroska, Amirreza Alijanpourotaghsara, David Strelnikov, Arsalan Vessal, Helga Szabo, Anita Hernyes, Luca Zoldi, Zsofia Jokkel, Andrea Fekete, Janos Juhasz, Nora Makra, Dora Szabo, Edit Buzas, Ada
Medicina.2023; 59(10): 1696. CrossRef - Dementia Prevention in Clinical Practice
Kellyann Niotis, Kiarra Akiyoshi, Caroline Carlton, Richard Isaacson
Seminars in Neurology.2022; 42(05): 525. CrossRef - Progressive Supranuclear Palsy in 2022: recent developments and an eye to the future
Shane Lyons, Sean O'Dowd, Richard Walsh, Tim Lynch
Advances in Clinical Neuroscience & Rehabilitation.2022;[Epub] CrossRef
- Parkinson’s Disease is Predominantly a Genetic Disease
First
Prev
